Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 54.84% | 21.65% | 7.48% | -4.66% | 0.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.71% | 21.73% | 7.56% | -4.58% | 0.12% |
| Cost of Revenue | 32.86% | -6.89% | -34.54% | -50.22% | -49.00% |
| Gross Profit | 62.91% | 34.70% | 34.75% | 34.24% | 56.83% |
| SG&A Expenses | 6.92% | -0.61% | -3.48% | -5.60% | -5.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.89% | -2.28% | -12.73% | -20.67% | -21.26% |
| Operating Income | 212.57% | 143.08% | 76.57% | 65.19% | 63.41% |
| Income Before Tax | 173.20% | 115.89% | 62.32% | 55.66% | 57.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 169.69% | 115.89% | 62.32% | 55.66% | 57.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 169.69% | 115.89% | 62.32% | 55.66% | 57.16% |
| EBIT | 212.57% | 143.08% | 76.57% | 65.19% | 63.41% |
| EBITDA | 230.45% | 154.83% | 80.12% | 67.21% | 64.92% |
| EPS Basic | 168.47% | 115.55% | 62.69% | 56.07% | 57.54% |
| Normalized Basic EPS | 169.17% | 114.55% | 66.41% | 56.91% | 58.11% |
| EPS Diluted | 163.94% | 112.85% | 61.54% | 55.15% | 56.85% |
| Normalized Diluted EPS | 167.97% | 114.42% | 66.41% | 56.91% | 58.11% |
| Average Basic Shares Outstanding | 1.05% | 0.97% | 0.95% | 0.88% | 0.91% |
| Average Diluted Shares Outstanding | 1.59% | 1.05% | 0.97% | 0.89% | 0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |